Our ‘peace of mind’ page

Testing for chemical compounds was completed by an independent, OEKO-TEX® laboratory and certification was granted in March 2025.

The Diaper adheres to the EDANA Stewardship Programme Standard and was certified to OEKO-TEX® STANDARD 100 for safety from numerous chemicals that may be considered toxic or harmful for use. The Diaper was evaluated, and proven to be safe (free of, below detectable levels, or significantly below allowed levels) from over 1,000 compounds, including:

Testing for chemical compounds was completed by an independent laboratory in March 2023. Certification to OEKO-TEX® STANDARD 100 is in progress.

The Pant adheres to the EDANA Stewardship Programme Standard and was tested, and proven to be free, below detectable levels, or significantly below allowed levels (when regulation exists) for numerous chemicals that may be considered toxic or harmful for use, including:

Testing for chemical compounds was completed by an independent, OEKO-TEX® laboratory and certification was granted in April 2025.

The Swimsuit adheres to the EDANA Stewardship Programme Standard and is certified to OEKO-TEX® STANDARD 100 for safety from numerous chemicals that may be considered toxic or harmful for use. The Swimsuit was evaluated, and proven to be safe (free of, below detectable levels, or significantly below allowed levels) from over 1,000 compounds, including:

Testing for chemical compounds was completed by an independent, OEKO-TEX® laboratory and certification was granted in March 2025.

The Wipe was certified to OEKO-TEX® STANDARD 100 for safety from numerous chemicals that may be considered toxic or harmful for use. The Wipe was evaluated, and proven to be safe (free of, below detectable levels, or significantly below allowed levels) from:

Testing for chemical compounds was completed by an independent, OEKO-TEX® laboratory and certification was granted in March 2025.

The Soft Wipe was certified to OEKO-TEX® STANDARD 100 for safety from numerous chemicals that may be considered toxic or harmful for use. The Soft Wipe was evaluated, and proven to be safe (free of, below detectable levels, or significantly below allowed levels) from:

Testing for chemical compounds was completed by an independent, OEKO-TEX® laboratory and certification was granted in March 2025.

The Flush Wipe was certified to OEKO-TEX® STANDARD 100 for safety from numerous chemicals that may be considered toxic or harmful for use. The Flush Wipe was evaluated, and proven to be safe (free of, below detectable levels, or significantly below allowed levels) from:

Hypoallergenicity Testing - HRIPT Report

A clinical HRIPT test was conducted between March 17, 2025 and April 24, 2025, under the supervision of a dermatologist. This study aims to show the absence of Primary Irritability, Accumulated Dermal Irritability, and Dermal Sensitization potentials of a product for topical use. There were no reports or evidence of adverse reaction during the study (irritation index: 0.00), proving First Wash’s safety for topical use, and supporting the claims dermatologically tested, suitable for all skin types and sensitive skin.

in vivo Microbiome Product Testing Report

The skin microbiome is a unique ecosystem of microorganisms that plays a critical role in maintaining skin health. Understanding and maintaining a balanced skin microbiome is essential for addressing skin concerns effectively. In vivo testing—conducted directly on the living skin—captures real-world dynamics (microbiome, environmental stressors, sweat, and sebum interactions), offering a more accurate assessment of how products affect the skin microbiome’s natural balance over time.

This clinical study evaluated the effect of First Wash on the skin microbiome. By using First Wash, individuals positively promote the maintenance of a healthy skin microbiome ecosystem, maintaining a natural bacterial diversity, and balanced microbiome. Additionally, there was found to be no significant increase in pathogenic bacteria such as Staphylococcus aureus or Prevotella melaninogenica typically associated with atopic dermatitis.

Ocular Irritability Ophthalmological Clinical Study

A controlled, randomized ophthalmological clinical study to evaluate ocular irritability via instillation procedure was conducted between March 17, 2025 and March 20, 2025. The aim of this study is to investigate the safety of First Wash with regard to the potential for eye irritation and absence of tears. First Wash presented an ocular irritability index <2.0 for all evaluated requirements.

Product pH

pH is used to express acidity and alkalinity on a scale of 0 (most acidic)-14 (most alkaline). Normal values of pH in healthy skin are slightly acidic, around 5.5, due to the presence of the acid mantle. First Wash is formulated to target a product pH that mimics the range of baby’s skin pH, balanced by the use of citric acid.

Hypoallergenicity Testing - HRIPT Report

A clinical HRIPT test was conducted between March 17, 2025 and April 24, 2025, under the supervision of a dermatologist. This study aims to show the absence of Primary Irritability, Accumulated Dermal Irritability, and Dermal Sensitization potentials of a product for topical use. There were no reports or evidence of adverse reaction during the study (irritation index: 0.00), proving Soft Cream’s safety for topical use, and supporting the claims dermatologically tested, suitable for all skin types and sensitive skin.

in vivo Microbiome Product Testing Report

The skin microbiome is a unique ecosystem of microorganisms that plays a critical role in maintaining skin health. Understanding and maintaining a balanced skin microbiome is essential for addressing skin concerns effectively. In vivo testing—conducted directly on the living skin—captures real-world dynamics (microbiome, environmental stressors, sweat, and sebum interactions), offering a more accurate assessment of how products affect the skin microbiome’s natural balance over time.

This clinical study evaluated the effect of Soft Cream on the skin microbiome. By using Soft Cream, individuals positively promote the maintenance of a healthy skin microbiome ecosystem, maintaining a natural bacterial diversity, and balanced microbiome. Additionally, there was found to be no significant increase in pathogenic bacteria such as Staphylococcus aureus or Prevotella melaninogenica typically associated with atopic dermatitis.

Product pH

pH is used to express acidity and alkalinity on a scale of 0 (most acidic)-14 (most alkaline). Normal values of pH in healthy skin are slightly acidic, around 5.5, due to the presence of the acid mantle. Soft Cream is formulated to target a product pH that mimics the range of baby’s skin pH, balanced by the use of citric acid.

Hypoallergenicity Testing - HRIPT Report

A clinical HRIPT test was conducted between March 17, 2025 and April 24, 2025, under the supervision of a dermatologist. This study aims to show the absence of Primary Irritability, Accumulated Dermal Irritability, and Dermal Sensitization potentials of a product for topical use. There were no reports or evidence of adverse reaction during the study (irritation index: 0.00), proving Bun Balm’s safety for topical use, and supporting the claims dermatologically tested, suitable for all skin types and sensitive skin.

in vivo Microbiome Product Testing Report

The skin microbiome is a unique ecosystem of microorganisms that plays a critical role in maintaining skin health. Understanding and maintaining a balanced skin microbiome is essential for addressing skin concerns effectively. In vivo testing—conducted directly on the living skin—captures real-world dynamics (microbiome, environmental stressors, sweat, and sebum interactions), offering a more accurate assessment of how products affect the skin microbiome’s natural balance over time.

This clinical study evaluated the effect of Bun Balm on the skin microbiome. By using Bun Balm, individuals positively promote the maintenance of a healthy skin microbiome ecosystem, maintaining a natural bacterial diversity, and balanced microbiome. Additionally, there was found to be no significant increase in pathogenic bacteria such as Staphylococcus aureus or Prevotella melaninogenica typically associated with atopic dermatitis.

Ocular Irritability Ophthalmological Clinical Study

A controlled, randomized ophthalmological clinical study to evaluate ocular irritability via instillation procedure was conducted between March 17, 2025 and March 20, 2025. The aim of this study is to investigate the safety of Bun Balm with regard to the potential for eye irritation to support use on the face. Bun Balm presented an ocular irritability index <2.0 for all evaluated requirements.